Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification
AUTOR(ES)
DePrimo, Samuel E
FONTE
BioMed Central
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=152639Documentos Relacionados
- A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer
- Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection
- Decreased expression of chromodomain helicase DNA-binding protein 9 is a novel independent prognostic biomarker for colorectal cancer
- Clinical responses with active specific intralymphatic immunotherapy for cancer--a phase I-II trial.
- Gene expression profiling of clinical stages II and III breast cancer